• 1
    Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497504
  • 2
    Heidenreich A, Bolla M, Joniau S et al. EAU Guidelines on Prostate Cancer 2011. Available at: Accessed July 2012
  • 3
    Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 10214
  • 4
    Morote J, Orsola A, Planas T et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 12905
  • 5
    Melton LJ 3rd, Alothman KI, Achenbach SJ, O'Fallon WM, Zincke H. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000. Mayo Clinic Proc 2001; 76: 1199203
  • 6
    Machtens S, Schultheiss D, Kuczyk M, Truss MC, Jonas U. The history of endocrine therapy of benign and malignant diseases of the prostate. World J Urol 2000; 18: 2226
  • 7
    Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 10117
  • 8
    Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 1988; 7: 16570
  • 9
    The Leuprolide Study Group. Leuprolide versus diethylstilbesterol for metastatic prostate cancer. N Engl J Med 1984; 311: 12816
  • 10
    Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 124762
  • 11
    Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10: 70920
  • 12
    Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU Int 2000; 85: 6905
  • 13
    Labrie F, Dupont A, Belanger A, Emond J, Monfette G. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 1984; 81: 38613
  • 14
    Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58 (Suppl. 1): 59
  • 15
    Seidenfield J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 56677
  • 16
    Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 57283
  • 17
    McLeod DG, Zinner N, Tomera K et al. A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2003; 61 (Suppl. 1): 37
  • 18
    Trachtenberg J, Gittleman M, Steidle C et al. A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 16704
  • 19
    Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-42
  • 20
    Decensi AU, Boccardo F, Guarneri D et al. Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146: 37781
  • 21
    Desai A, Stadler WM, Vogelzang N. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001; 58: 101620
  • 22
    Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169: 174244
  • 23
    Tyrrell CJ, Kaisary AV, Iversen P et al. A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 44756
  • 24
    Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164: 157982
  • 25
    Boccardo F, Barichello M, Battaglia M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42: 48190
  • 26
    Heidenreich A. Current approach to androgen deprivation therapy in patients with advanced prostate cancer. Eur Urol 2010; 9: 77681
  • 27
    Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975; 2: 125140
  • 28
    Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 227582
  • 29
    Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 27383
  • 30
    Mottet N, Costa P, Navratil H. Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study. Prost Canc Prostatic Dis 1999; 2 (Suppl. 2): S2S4
  • 31
    Theyer G, Hamilton G. Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 1998; 52: 3539
  • 32
    Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer 1993; 71: 278290
  • 33
    Sato N, Gleave ME, Bruchovsky N et al. Intermittent androgen suppression delays time to non-androgen regulated prostate specific antigen gene expression in the human prostate LNCaP tumor model. J Steroid Biochem Molec Biol 1996; 58: 13946
  • 34
    Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Canc Prostat Dis 1998; 1: 28996
  • 35
    Woolf JM, Tunn UW. Intermittent androgen blockade in prostate cancer: rational and clinical experience. Eur Urol 2000; 38: 36571
  • 36
    Klotz LH, Herr HW, Morse MJ, Whitmore WFJr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 254650
  • 37
    Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 5304
  • 38
    Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999; 35 (Suppl. 1): 2731
  • 39
    Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005; 75: 2048
  • 40
    Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 126977
  • 41
    Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 4959
  • 42
    Lundgren R, Nordle O, Josefsson K. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicentre study with 15 years of followup. The South Sweden Prostate Cancer Study Group. J Urol 1995; 153: 15806
  • 43
    Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 186570
  • 44
    Schröder FH, Kurth KH, Fosså SD et al. Early versus delayed endocrine treatment of pN1–3 M0 prostate cancer without local treatment of the primary tumor: results of the European Organization for the Research and Treatment of Cancer 30846 – a phase III study. J Urol 2004; 172: 9237
  • 45
    Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Clin Oncol 2006; 24: 186876
  • 46
    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 23546
  • 47
    Schröder FH, Kurth KH, Fossa SD et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009; 55: 1422
  • 48
    Messing EM, Manola J, Yao J et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 4729
  • 49
    Bolla M. Current status of combined radiation therapy and androgen suppression in locally advanced prostate cancer: what is the way forward? Eur Urol 2010; 9 (Suppl.): 78893
  • 50
    Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long- term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 128590
  • 51
    Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000; 92: 158292
  • 52
    Isbarn H, Boccon-Gibod L, Carroll PR et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009; 55: 6275
  • 53
    Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167: 19526
  • 54
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 43944
  • 55
    Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 200812
  • 56
    Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 103842
  • 57
    Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 74555
  • 58
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 13058
  • 59
    Nguyen PL, Je Y, Schutz FA et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 235966
  • 60
    Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001; 30: 1019 (vii)
  • 61
    Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008; 8: 44957
  • 62
    Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 456371
  • 63
    Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 14818
  • 64
    De Bono J, Logothetis CJ, Fizazi K et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized, double-blind, placebo controlled phase III study. 35th ESMO Congress 2010; Abstract LBA5
  • 65
    Kaku T, Hitaka T, Ojida A et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19: 638399
  • 66
    Dreicer R, Agus DB, MacVicar GR et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Abstract presented at: 2010 Genitourinary Cancers Symposium; March 5–7, 2010; San Francisco,CA, abstract 103
  • 67
    Hussain M, Corn P, Michaelson D et al. Activity and safety of the investigational agent orteronel in men with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen: results of a Phase 2 study. Eur Urol 2012; 11 (Suppl.): abstract 124
  • 68
    Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 78790
  • 69
    Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 143746
  • 70
    Takeda, data on file